Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|73|3-4|204-209

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.3-4, 2008-04, pp. : 204-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 340-347

Karger

Access to resources Recommend Favorite

Downsizing a Thrombus of Advanced Renal Cell Carcinoma in a Presurgical Setting with Sorafenib

By  

Urologia Internationalis, Vol. 88, Iss. 2, 2011-12 ,pp. : 235-237

Karger

Access to resources Recommend Favorite

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 328-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Neoadjuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical Nephrectomy

By  

Urologia Internationalis, Vol. 80, Iss. 4, 2008-06 ,pp. : 451-453

Karger

Access to resources Recommend Favorite